Citizens Business Bank Sells 335 Shares of Eli Lilly and Company (NYSE:LLY)

Citizens Business Bank lowered its position in Eli Lilly and Company (NYSE:LLY) by 23.5% in the fourth quarter, HoldingsChannel.com reports. The fund owned 1,093 shares of the company’s stock after selling 335 shares during the quarter. Citizens Business Bank’s holdings in Eli Lilly and Company were worth $637,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Simon Quick Advisors LLC raised its position in Eli Lilly and Company by 10.5% in the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after purchasing an additional 278 shares during the last quarter. Clear Harbor Asset Management LLC acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at $363,000. Terril Brothers Inc. raised its holdings in shares of Eli Lilly and Company by 113.2% in the fourth quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock valued at $471,000 after buying an additional 429 shares during the last quarter. Hartline Investment Corp lifted its position in Eli Lilly and Company by 1.1% during the 4th quarter. Hartline Investment Corp now owns 21,934 shares of the company’s stock worth $12,786,000 after buying an additional 248 shares in the last quarter. Finally, Meritage Portfolio Management grew its holdings in Eli Lilly and Company by 23.4% during the 4th quarter. Meritage Portfolio Management now owns 6,377 shares of the company’s stock worth $3,717,000 after acquiring an additional 1,208 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 6.0 %

LLY traded up $44.36 during trading on Tuesday, reaching $781.56. The company had a trading volume of 7,432,651 shares, compared to its average volume of 3,071,009. The company has a market cap of $742.61 billion, a P/E ratio of 134.43, a PEG ratio of 1.60 and a beta of 0.34. Eli Lilly and Company has a 12 month low of $392.26 and a 12 month high of $800.78. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The business’s fifty day moving average price is $760.89 and its 200 day moving average price is $668.00.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating the consensus estimate of $2.30 by $0.19. The business had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm’s revenue was up 28.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.09 EPS. Equities analysts anticipate that Eli Lilly and Company will post 12.51 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on LLY. BMO Capital Markets increased their price target on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. Truist Financial reissued a “buy” rating and set a $850.00 price objective on shares of Eli Lilly and Company in a report on Friday, March 22nd. Barclays raised their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research note on Wednesday, February 7th. DZ Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a research note on Wednesday, February 21st. Finally, TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $731.55.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now directly owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.